Laboratorios Silanes S.A. de C.V.

Quick facts

Marketed products

• metformin/glimepiride combination · Endocrinology/Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while glimepiride stimulates pancreatic beta cells to increase insulin secretion, together lowering blood glucose in type 2 diabetes.

Phase 3 pipeline

• Celecoxi + Acetaminophen · Pain Management / Rheumatology
  Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
• Celecoxib + Acetaminohen · Pain Management / Rheumatology
  Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.
• Celecoxib + Vitamin B fixed dose · Rheumatology / Pain Management
  Celecoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce inflammation and pain, while B vitamins support metabolic and neurological function.
• Desloratadine / Betamethasone in fixed dose · Immunology / Allergy
  Desloratadine blocks histamine H1 receptors to reduce allergic symptoms, while betamethasone is a corticosteroid that suppresses inflammatory and immune responses.
• Dexketoprofen/Vitamin B · Pain Management / Rheumatology
  Dexketoprofen inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation, while vitamin B provides nutritional support and may enhance analgesic efficacy.
• Etoricoxib + Betamethasone fixed dose · Rheumatology / Inflammatory diseases
  Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation.
• Etoricoxib + Cyanocobalamin fixed dose · Pain management / Rheumatology
  Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while cyanocobalamin (vitamin B12) supports neurological function and red blood cell formation.
• Etoricoxib fixed dose · Rheumatology / Pain Management
  Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.
• Etoricoxib + Tizanidine fixed dose · Pain Management / Musculoskeletal Disorders
  Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while tizanidine acts as a central alpha-2 adrenergic agonist to relieve muscle tension.
• Fixed Dose Etoricoxib + Betamethasone · Rheumatology / Inflammatory Diseases
  Etoricoxib selectively inhibits COX-2 to reduce inflammation and pain, while betamethasone provides additional anti-inflammatory and immunosuppressive effects via glucocorticoid receptor activation.
• Ibuprofen + Loratadine fixed dose · Pain management and Allergy/Immunology
  Ibuprofen reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while loratadine blocks histamine H1 receptors to relieve allergic symptoms.
• Losartan/Chlorthalidone in fixed dose · Cardiovascular
  Losartan blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.
• Losartan + hydrochlorothiazide in fixed dose · Cardiovascular
  Losartan blocks angiotensin II receptors to reduce vasoconstriction, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure.
• Monotherapy Etoricoxib · Rheumatology / Pain Management
  Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.
• Pregabalin + Vitamin B fixed dose · Neurology
  Pregabalin binds to voltage-gated calcium channels to reduce neurotransmitter release, while B vitamins support nerve function and myelin integrity.
• Sibutramine-Metformin · Endocrinology / Obesity / Diabetes
  Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism.

Phase 2 pipeline

• DMMET-01

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Laboratorios Silanes S.A. de C.V. portfolio CI brief
• Laboratorios Silanes S.A. de C.V. pipeline updates RSS